Viking Therapeutics, Inc. is advancing VK2735, a dual GLP-1/GIP agonist, targeting the obesity and diabetes market. I rate VKTX stock as Hold. Read my full update now.
CryptoAlerta — análise de criptomoedas e mercado em tempo real